SUNSHINE BIOPHARMA INC (SBFM) Stock Price, Quote, News and Overview
NASDAQ:SBFM - Nasdaq - US8677817004 - Common Stock - Currency: USD
SBFM Quote, Performance and Key Statistics
1.44
+0.04 (+2.86%)
The current stock price of SBFM is 1.44 USD. In the past month the price decreased by -4.64%. In the past year, price decreased by -90.46%.
SBFM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 324.18B | ||
| AMGN | AMGEN INC | 13.09 | 146.06B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.72B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.84B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About SBFM
Company Profile
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Fort Lauderdale, Florida and currently employs 52 full-time employees. The company went IPO on 2008-08-15. The firm has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The firm operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The firm operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Company Info
SUNSHINE BIOPHARMA INC
333 Las Olas Way, Cu4 Suite 433
FORT LAUDERDALE FLORIDA US
Employees: 44
Phone: 19545150810
SUNSHINE BIOPHARMA INC / SBFM FAQ
What is the stock price of SUNSHINE BIOPHARMA INC today?
The current stock price of SBFM is 1.44 USD. The price increased by 2.86% in the last trading session.
What is the ticker symbol for SUNSHINE BIOPHARMA INC stock?
The exchange symbol of SUNSHINE BIOPHARMA INC is SBFM and it is listed on the Nasdaq exchange.
On which exchange is SBFM stock listed?
SBFM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SUNSHINE BIOPHARMA INC stock?
7 analysts have analysed SBFM and the average price target is 306 USD. This implies a price increase of 21150% is expected in the next year compared to the current price of 1.44. Check the SUNSHINE BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SUNSHINE BIOPHARMA INC worth?
SUNSHINE BIOPHARMA INC (SBFM) has a market capitalization of 6.57M USD. This makes SBFM a Nano Cap stock.
How many employees does SUNSHINE BIOPHARMA INC have?
SUNSHINE BIOPHARMA INC (SBFM) currently has 44 employees.
What are the support and resistance levels for SUNSHINE BIOPHARMA INC (SBFM) stock?
SUNSHINE BIOPHARMA INC (SBFM) has a support level at 1.23 and a resistance level at 1.51. Check the full technical report for a detailed analysis of SBFM support and resistance levels.
Is SUNSHINE BIOPHARMA INC (SBFM) expected to grow?
The Revenue of SUNSHINE BIOPHARMA INC (SBFM) is expected to grow by 164.69% in the next year. Check the estimates tab for more information on the SBFM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SUNSHINE BIOPHARMA INC (SBFM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SBFM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SBFM, evaluating the profitability, health, valuation and growth aspects
- SUNSHINE BIOPHARMA INC (SBFM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SUNSHINE BIOPHARMA INC (SBFM) Sales and EPS estimates to see what analysts future expectations are.
- SUNSHINE BIOPHARMA INC (SBFM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SUNSHINE BIOPHARMA INC (SBFM) Insider and Institutional Ownership to learn about the owners and their transactions.
- SUNSHINE BIOPHARMA INC (SBFM) Stock Chart to make your own analysis
- SUNSHINE BIOPHARMA INC (SBFM) Latest news and press-releases to stay up to date.
Does SUNSHINE BIOPHARMA INC (SBFM) stock pay dividends?
SBFM does not pay a dividend.
When does SUNSHINE BIOPHARMA INC (SBFM) report earnings?
SUNSHINE BIOPHARMA INC (SBFM) will report earnings on 2025-08-14.
What is the Price/Earnings (PE) ratio of SUNSHINE BIOPHARMA INC (SBFM)?
SUNSHINE BIOPHARMA INC (SBFM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-51.88).
What is the Short Interest ratio of SUNSHINE BIOPHARMA INC (SBFM) stock?
The outstanding short interest for SUNSHINE BIOPHARMA INC (SBFM) is 11.33% of its float. Check the ownership tab for more information on the SBFM short interest.
SBFM Technical Analysis
SBFM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SBFM. While SBFM seems to be doing ok healthwise, there are quite some concerns on its profitability.
SBFM Financial Highlights
Over the last trailing twelve months SBFM reported a non-GAAP Earnings per Share(EPS) of -51.88. The EPS increased by 7.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.23% | ||
| ROE | -22.16% | ||
| Debt/Equity | 0 |
SBFM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SBFM. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 101.45% and a revenue growth 164.69% for SBFM